[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 17, 1998

Merck-Sponsored Simvastatin (Zocor) Compliance Program for Patients Using Wal-Mart Pharmacy: Of Benefit to Whom?

Author Affiliations
 

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(23):1875-1876. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-23-jbk0617

To the Editor.— I received in the mail September 10, 1997, a notice from Wal-Mart Pharmacy that they are concerned that "coronary heart disease remains a leading cause of morbidity and mortality," and are "going to do something about it." They then inform me that they can help ensure that my patients who are "at increased risk" receive—and stay with—the treatment [I] prescribe." This is especially important with patients who are receiving Zocor (simvastatin), they say, because Zocor has been proven to save lives.

First Page Preview View Large
First page PDF preview
First page PDF preview
×